CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

How to Use Clinical Trial Matching Software for The Trials?

How to Use Clinical Trial Matching...

StudyKIK Acquired by Syneos Health to Deliver Patient and Physician Benefits

StudyKIK Acquired by Syneos Health to...

Syneos Health Partners with Ride Health

Syneos Health Partners with Ride Health

How Patient Recruitment Technologies Can Enhance Clinical Trials

How Patient Recruitment Technologies...

Patient Recruitment: Market and Strategies

Patient Recruitment: Market and...

How Digital Transformation Has Impacted Patient Recruiting and Engagement Initiatives

How Digital Transformation Has...

The Need for Digital Shift in Patient Recruitment and Engagement

The Need for Digital Shift in Patient...

Why has Technology Become Essential in Patient Recruitment?

Why has Technology Become Essential...

How to Use Clinical Trial Matching Software for The Trials?

How to Use Clinical Trial Matching...

StudyKIK Acquired by Syneos Health to Deliver Patient and Physician Benefits

StudyKIK Acquired by Syneos Health to...

Syneos Health Partners with Ride Health

Syneos Health Partners with Ride Health

How Patient Recruitment Technologies Can Enhance Clinical Trials

How Patient Recruitment Technologies...

Patient Recruitment: Market and Strategies

Patient Recruitment: Market and...

How Digital Transformation Has Impacted Patient Recruiting and Engagement Initiatives

How Digital Transformation Has...

The Need for Digital Shift in Patient Recruitment and Engagement

The Need for Digital Shift in Patient...

Why has Technology Become Essential in Patient Recruitment?

Why has Technology Become Essential...

Advanced HPV-16 Positive Head and Neck Cancer: PDS Biotech Enlists First Stage of Checkpoint Inhibitor Nave Patients

Life Sciences Review Life Sciences Review | Monday, October 25, 2021
Tweet

PDS Biotech incorporates the first stage of a checkpoint inhibitor-naive patient arm into a phase 2 clinical trial for advanced HPV-16 positive head and neck cancer.


FREMONT, CA: Clinical trials are a critical component of medical research that advances medical knowledge and patient treatment. They are critical for identifying novel therapies for diseases and new methods for detecting, diagnosing, and preventing disease development. Additionally, clinical trials assist physicians in determining if the adverse effects of new medication are tolerable when weighed against the possible benefits. PDS Biotechnology Corporation enrolls itself for the first stage of the checkpoint inhibitor naive arm of its VERSATILE-002 Phase 2 study to treat recurrent or metastatic human papillomavirus (HPV16)-associated head and neck cancer has been completed. The company is known for developing novel cancer therapies based on the company's proprietary Versamune® T-cell activating technology. Dr. Jared Weiss is the Lead Principal Investigator of VERSATILE-002. He is a Section Chief of Thoracic and Head and Neck Oncology at the University of North Carolina in Chapel Hill School of Medicine and Lineberger Comprehensive Cancer Center.


Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech, says, "Completion of enrollment among checkpoint inhibitor naive patients in this first stage of our VERSATILE-002 Phase 2 study in the CPI naive arm is an important milestone, and we would like to thank the patients for their participation in this clinical trial. Through their involvement, together with site Investigators and study staff, this trial will help us better understand the potential contribution that PDS0101 may have in improving the lives of patients with advanced head and neck cancer."


VERSATILE-002 is a study of two groups of individuals with HPV16-positive head and neck cancer who have had their disease recur or spread. The first group has never received a checkpoint inhibitor before (CPI naive). The second group of patients has been treated unsuccessfully numerous times, including checkpoint inhibitor therapy (CPI refractory). The clinical trial design defines the objective response as determined using RECIST 1.1 radiographic tumor responses (tumor reduction of 30 percent or more). If at least four of the initial 17 patients in the CPI naive arm show an objective response, the research will continue to the second stage and recruit the anticipated 54 patients in the CPI naive arm. Merck & Co. is collaborating on the experiment.


Weekly Brief

loading
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/advanced-hpv16-positive-head-and-neck-cancer-pds-biotech-enlists-first-stage-of-checkpoint-inhibitor-nave-patients-nwid-606.html